Sign In
Buy ASRT
$23.47
+0.0200 (+0.0853%)
At Close: Jun 03, 2026
Assertio to Participate in the iAccess Alpha Virtual Best Ideas Conference on March 25-26, 2025
09:10am, Thursday, 20'th Mar 2025
LAKE FOREST, Ill., March 20, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that Brendan O'Grady, Chief Executive Officer, will p
Assertio Holdings, Inc. (ASRT) Q4 2024 Earnings Call Transcript
06:53pm, Wednesday, 12'th Mar 2025
Assertio Holdings, Inc. (NASDAQ:ASRT ) Q4 2024 Earnings Conference Call March 12, 2025 4:30 PM ET Company Participants Matthew Kreps - IR Brendan O'Grady - CEO Ajay Patel - CFO Conference Call Partici
Assertio Reports Fourth Quarter and Full Year 2024 Financial Results
04:05pm, Wednesday, 12'th Mar 2025
Fourth Quarter Net Product Sales $29.6 Million, Cash Flow from Operations of $11.5 Million Full Year Net Product Sales $120.8 Million, Rolvedon Sales Exceed $60.0 Million Full Year Cash Flow from Oper
Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025
04:05pm, Wednesday, 05'th Mar 2025
LAKE FOREST, Ill., March 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that it will release fourth quarter and full year 202
CHICAGO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed in Lake County Circuit Court, Nineteenth Judicial Circuit, State of Illinois, on behalf of all persons and entities who
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:30pm, Friday, 03'rd Jan 2025
LAKE FOREST, Ill., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities o
Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors
08:30am, Tuesday, 17'th Dec 2024
LAKE FOREST, Ill., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities o
Assertio Announces Results of Rolvedon® (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study
08:00am, Friday, 13'th Dec 2024
LAKE FOREST, Ill., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities o
New Strong Buy Stocks for December 10th
08:01am, Tuesday, 10'th Dec 2024
CTV, GRAB, ASRT, POWL and LUV have been added to the Zacks Rank #1 (Strong Buy) List on December 10, 2024.
New Strong Buy Stocks for November 29th
06:36am, Friday, 29'th Nov 2024
MKTAY, ASRT, CHH, DRS and BRKL have been added to the Zacks Rank #1 (Strong Buy) List on November 29, 2024.
Buxton Helmsley Calls for Senate Hearing on Well-Documented Evident Clinical Data Fraud at Assertio
09:00am, Friday, 15'th Nov 2024
NEW YORK--(BUSINESS WIRE)--The Buxton Helmsley Group, Inc. (together with certain of its affiliates, “BHG” or “we”), a New York City-based investment fund manager that recently inverted its lo
Assertio Holdings, Inc. (ASRT) Q3 2024 Earnings Call Transcript
06:57pm, Monday, 11'th Nov 2024
Call Start: 16:30 January 1, 0000 5:03 PM ET Assertio Holdings, Inc. (NASDAQ:ASRT ) Q3 2024 Earnings Conference Call November 11, 2024 04:30 PM ET Company Participants Matthew Kreps - Darrow Associate
Assertio (ASRT) Reports Q3 Loss, Lags Revenue Estimates
06:11pm, Monday, 11'th Nov 2024
Assertio (ASRT) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to earnings of $0.01 per share a year ago.
Assertio Reports Third Quarter 2024 Financial Results
04:02pm, Monday, 11'th Nov 2024
Third Quarter Total Net Product Sales of $28.7 Million Rolvedon Net Product Sales of $15.0 Million Cash and Short-Term Investments of $88.6 Million LAKE FOREST, Ill., Nov. 11, 2024 (GLOBE NEWSWIRE)
Buxton Helmsley Releases Evidence of Product-Related Fraud at Assertio
03:41pm, Monday, 11'th Nov 2024
NEW YORK--(BUSINESS WIRE)--The Buxton Helmsley Group, Inc. (together with certain of its affiliates, “BHG” or “we”), a New York City-based investment fund manager that has inverted its long eq
